Price Target Changed • Jul 09
Price target decreased by 45% to US$12.20 Down from US$22.25, the current price target is provided by 1 analyst. New target price is 784% above last closing price of US$1.38. Stock is down 54% over the past year. The company is forecast to post a net loss per share of US$1.17 next year compared to a net loss per share of US$2.65 last year. Announcement • Jul 04
Bone Biologics Corporation, Annual General Meeting, Aug 11, 2026 Bone Biologics Corporation, Annual General Meeting, Aug 11, 2026. Location: bone biologics corporation offices, 2 burlington woods drive, ste 100, ma 01803, burlington United States Announcement • May 21
Bone Biologics Corporation Achieves 29-Month Validated Shelf Life for rhNELL-1 Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the Company progresses rhNELL-1 toward the manufacturing scale required for a future pivotal study. The Company previously stated its objective of achieving a shelf life sufficient to support scaled manufacturing ahead of a pivotal study. The 29-month validation is expected to bring the program meaningfully closer to that threshold. NB1, the Company's lead product candidate, combines rhNELL-1 protein with demineralized bone matrix to provide controlled bone regeneration. Bone Biologics is currently conducting a multicenter, prospective, randomized pilot clinical study evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion in Australia. New Risk • Sep 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (498% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.72m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.5m net loss next year). Announcement • Jun 28
Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million. Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,250,000
Price\Range: $4
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 1,250,000
Security Name: Series D Warrants
Security Type: Equity Warrant
Securities Offered: 1,250,000
Security Name: Series E Warrants
Security Type: Equity Warrant
Securities Offered: 1,250,000 Announcement • Jun 27
Bone Biologics Corporation Files Patent Application for Bone Regeneration Technology Bone Biologics Corporation announced the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio and support the Company's strategic plan to advance the clinical development program. Announcement • Jun 25
Bone Biologics Corporation has filed a Follow-on Equity Offering. Bone Biologics Corporation has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 846,023
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 846,023
Security Name: Series D Warrants
Security Type: Equity Warrant
Securities Offered: 846,023
Security Name: Series E Warrants
Security Type: Equity Warrant
Securities Offered: 846,023 New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.47m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). New Risk • May 15
New major risk - Revenue and earnings growth Earnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.42m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). New Risk • May 13
New major risk - Revenue and earnings growth Earnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (272% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.39m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$3.8m net loss next year). Announcement • Apr 12
Bone Biologics Corporation Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price On April 7, 2025, Bone Biologics Corporation (the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price requirement. If the Company evidences a closing bid price of at least $1 per share for a minimum of 10 consecutive business days during the 180-day compliance period, the Company will regain compliance. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company's common stock on Nasdaq. The Company intends to monitor the closing bid price of its common stock and consider its available options in the event the closing bid price of its common stock remains below $1 per share. The Company intends to seek stockholder approval for a reverse stock split of its outstanding common stock at its upcoming annual meeting of stockholders. If the closing bid price of the common stock remains below $1 per share and the stockholders approve the proposal, the Company's Board of Directors may authorize a reverse stock split to attempt to increase the per share price of the common stock and regain compliance with the Nasdaq Listing Standards. Announcement • Apr 04
Bone Biologics Corporation, Annual General Meeting, May 30, 2025 Bone Biologics Corporation, Annual General Meeting, May 30, 2025. New Risk • Nov 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (44% average weekly change). Shareholders have been substantially diluted in the past year (435% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.50m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years). Announcement • Oct 21
Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors Bone Biologics Corporation announced the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He has broad experience representing diverse and innovative orthopedic and spine industry companies in developing and distributing innovative products. Mr. Meikle has been a consultant to Stryker Spine for the past five years. Biosystems of New England served as a distributor for Stryker Spine from 2002 to 2019, and for Medtronic Spine from 1992 to 2002. Mr. Meikle holds a B.S. from West Virginia University College of Engineering. He has received numerous professional awards including Inaugural Inductee in the Stryker Spine Hall of Fame and Distributor of the year at both Stryker and Medtronic Danek Spine. Announcement • Oct 07
Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately On October 1, 2024, Don Hankey informed Bone Biologics Corporation of his resignation as a director of the Company effective immediately. Mr. Hankey’s departure was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company is appreciative of Mr. Hankey’s years of service to the Company as a director. Announcement • Sep 28
Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million. Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Announcement • Aug 09
Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024 Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024. Location: 2 burlington woods drive, ste 100, ma 01803, burlington United States New Risk • Jul 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.38m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years). Announcement • Jun 21
Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion Bone Biologics Corporation announced that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD) and will evaluate safety and effectiveness, fusion success, pain, function improvement and adverse events. To be enrolled in the study, patients must have DDD at one level from L2-S1 and may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level. These two patients were treated in Australia. The study design was previously reviewed and agreed upon by the U.S. Food and Drug Administration’s Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States. Lumbar DDD is one of the most common causes of low back pain. DDD also leads to substantial disability, with many patients suffering from decreased ability to walk, sit, stand and/or sleep. For some people, DDD is part of the natural process of growing older and is a significant medical issue that is increasing as the global population ages. Announcement • Mar 05
Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million. Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 119,000
Price\Range: $2.56
Discount Per Security: $0.1792
Security Name: Common Warrants
Security Type: Equity Warrant
Securities Offered: 781,251
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 662,251
Price\Range: $2.559
Discount Per Security: $0.1792 Announcement • Mar 04
Bone Biologics Corporation has completed a Follow-on Equity Offering. Bone Biologics Corporation has completed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 781,251
Price\Range: $2.56
Security Name: Common Warrants
Security Type: Equity Warrant
Securities Offered: 781,251 New Risk • Feb 23
New major risk - Revenue and earnings growth Earnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.92m market cap). Announcement • Jan 31
Bone Biologics Corporation has filed a Follow-on Equity Offering. Bone Biologics Corporation has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Prefunded Warrants
Security Type: Equity Warrant
Security Name: Common Warrants
Security Type: Equity Warrant Announcement • Jan 11
Bone Biologics Corporation Announces Board Changes Bone Biologics Corporation announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon’s appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RNA processing to address hard-to-drug disease drivers. Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. He served as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. He was Chief Business Officer and Chief Financial Officer at Verastem Oncology. Before that, he was Chief Financial Officer at Harvard Bioscience Inc. Mr. Gagnon served as Executive Vice President, Chief Financial Officer, and Treasurer at Clean Harbors Inc. as well as Chief Accounting Officer and Controller at Biogen Idec Inc.Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an MBA from the MIT Sloan School of Management and a BA in Accounting from Bentley College. Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech. Announcement • Jan 10
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements Bone Biologics Corporation announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics was notified by Nasdaq on September 27, 2023 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on January 4, 2024, the 10th consecutive trading day when the closing bid price of the Company's common stock was over $1.00. Announcement • Nov 21
Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million. Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,139,063
Price\Range: $0.64
Discount Per Security: $0.0448
Transaction Features: Registered Direct Offering Announcement • Nov 18
Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million. Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,139,063
Price\Range: $0.64
Transaction Features: Registered Direct Offering Announcement • Oct 01
Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq On September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Accordingly, the Nasdaq staff has determined to delist the Company’s securities from Nasdaq (the “Staff Determination”). The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), to appeal the Staff Determination, which request will stay any delisting action pending the issuance of the Panel’s determination. At the hearing, the Company expects to present its plan for regaining and sustaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company any additional time to regain compliance or that the Company will ultimately regain and sustain compliance for listing of its securities on Nasdaq. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform. The Company is evaluating several alternatives to regain compliance with the minimum bid price requirement. New Risk • Aug 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.55m market cap). Announcement • Aug 04
Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023 Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023, at 11:00 US Eastern Standard Time. Location: 2 Burlington Woods Drive, Ste 100, Burlington MA 01803 Burlington Massachusetts United States Agenda: To consider elect four directors to our Board of Directors; to consider executive officer compensation; to consider approve, in an advisory (non-binding) vote, the frequency of future advisory votes on executive officer compensation; to consider ratify the appointment of Weinberg & Company, P.A., as our independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider approve an amendment to our 2015 Equity Incentive Plan; and to consider other matters. New Risk • Jun 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.19m market cap). Announcement • May 22
Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement Bone Biologics Corporation announced that as previously disclosed on November 21, 2022 in the Current Report on Form 8-K filed by the company, on November 17, 2022, the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business day period, the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and that it had been provided a 180-calendar day grace period to regain compliance with that requirement, which period expired May 16, 2023. The Company was not eligible to obtain an additional second 180 calendar period to regain compliance because as of March 31, 2023, the Company did not meet the initial listing standard for stockholders equity. On May 18, 2023, the Company was notified by the Staff that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as of May 30, 2023, the Company’s securities, common stock and publically traded warrants, were subject to delisting unless the Company timely appeals the Staff’s determination by requesting a hearing before the Nasdaq Hearings Panel (the ‘Panel’). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of the Panel’s decision following the hearing and the expiration of any extension that may be granted by the Panel. In connection with regaining compliance, on May 1, 2023, the Company received the approval of the requisite number of holders of the shares of its common stock to amend its certificate of incorporation to effect a reverse split of the shares of its common stock at a ratio of 1-for-20 to 1-for-50 (or any number in between), with the exact ratio to be set within such range in the discretion of the Company’s board of directors without further approval or authorization of the Company’s stockholders. The Company believes that the reverse split should increase its bid price such that the Company meets the minimum bid requirement. Once the Company regains compliance with the minimum bid request, the Company will then be subject to the continuing listing requirements regarding stockholders equity which the Company currently satisfies. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform. Announcement • Dec 24
Bone Biologics Corporation Resigns Stephen Laneve as Director Effective December 18, 2022 Stephen LaNeve resigned as a director of the Bone Biologics Corporation. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Announcement • Nov 22
Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement On November 17, 2022, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until May 16, 2023, to regain compliance with the minimum closing bid price requirement. If the Company does not regain compliance during the compliance period ending May 16, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum closing bid price requirement, and (ii) notify Nasdaq of its intent to cure the deficiency. The Company can achieve compliance with the minimum closing bid price requirement if, during either compliance period, the minimum closing bid price per share of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days. The Company anticipates that its shares of common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period(s). The Company plans to carefully assess potential actions to regain compliance. However, the Company may be unable to regain compliance with the minimum closing bid price requirement during the compliance period(s), in which case the Company anticipates Nasdaq would provide a notice to the Company that its shares of common stock are subject to delisting, and the Company’s common shares would thereupon be delisted. Price Target Changed • Nov 16
Price target decreased to US$4.88 Down from US$7.90, the current price target is an average from 2 analysts. New target price is 1,416% above last closing price of US$0.32. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.16 last year. Price Target Changed • Oct 22
Price target decreased to US$4.88 Down from US$7.90, the current price target is an average from 2 analysts. New target price is 823% above last closing price of US$0.53. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$0.36 next year compared to a net loss per share of US$0.16 last year. Announcement • Oct 14
Bone Biologics Corporation has completed a Composite Units Offering. Bone Biologics Corporation has completed a Composite Units Offering.
Security Name: Units
Security Type: Equity/Preferred Unit
Securities Offered: 3,777,778
Price\Range: $1.35 Announcement • Oct 08
Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million. Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,777,778
Price\Range: $1.35 Announcement • Jul 07
Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022 Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022, at 11:00 US Eastern Standard Time. Location: at Bone Biologics Corporation offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803 Burlington United States Agenda: To elect five directors to Board of Directors; to approve, in an advisory (non-binding) vote, our executive officer compensation; to ratify the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year ending December 31, 2022; and to transact any other business as may properly come before the meeting or at any adjournment thereof. Board Change • Oct 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Bruce Stroever was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.